Caissa Capital Management ltd.'s Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed May 30, 2023
- Accession no.
- 0001929354-23-000011
- Filed
- May 30, 2023
- Trade date
- May 25-30, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $7.47K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Caissa Capital Management ltd.CIK 0001929354 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 25, 2023 | Common stock | PPurchaseAcquired | +2,000 | $2.77 | +$5,540 | 1,384,700 | Indirect | |
| May 30, 2023 | Common stock | PPurchaseAcquired | +671 | $2.87F2 | +$1,925.77 | 1,385,371 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.85 to $2.87, inclusive.
Referenced by the price of 1 transaction in Table I.